Pilot Study on Muscle, Tendon, and Neural Changes Post-Botulinum Toxin Injections in Post-stroke Spastic Equinovarus

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age40-60
SponsorUniversitaire Ziekenhuizen KU Leuven

About this trial

Poststroke spasticity significantly impairs function, particularly through the development of pes equinovarus. Botulinum toxin A (BoNT) injections into the medial gastrocnemius (MG) are a first-line treatment. Treatment outcomes and long-term responses to interventions can vary significantly between individual patients. Additionally, there is increasing concern about potential adverse effects on muscle morphology. Further research is essential to optimize treatment strategies and improve long-term outcomes in this population. Three-dimensional freehand ultrasound (3DfUS) and instrumented spasticity assessment (ISA) are two recently developed techniques that enable the evaluation of changes in muscle, tendon, and neural properties following BoNT injections for post-stroke spastic equinovarus. These methods hold promise for providing new insights into treatment effects. Before implementing these techniques in large-scale studies, a pilot study is required for accurate sample size calculations for a prospective observational study. This study includes a protocol for a non-blinded, non-randomized open-label longitudinal pilot study. The study was approved by the European Medicines Agency ( EU CT Number 2024-513158-32) by the University Hospitals Leuven ethical committee (ID S68672). Standard deviations and effect sizes of outcome measures obtained longitudinally with 3DfUS and ISA before and after BoNT injection into MG will inform sample size calculations for future research.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures

2. At least 18 years of age at the time of signing the Informed Consent Form (ICF)

3. Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner.

4. Pes equinovarus due to spasticity

Disqualifiers

Musculoskeletal or other neurological problems affecting the lower limb

Presence of spinal cord pathology that could lead to spasticity, ataxia, dystonia

Cognitive problems that impede measurements

Severe co-morbidities

Trial design

Design model

Single group

Treatments tested in this trial

  • threedimensional freehand ultrasound and instrumented spasticity assessment

    Diagnostic test

    To conduct a pilot study as guidance for a future observational study to evaluate changes in muscle, tendon and neural properties after botulinum neurotoxin-A (BoNT) treatment of spastic equinovarus in first-ever stroke patients by using Three Dimensional freehand Ultrasound (3DfUS) and Instrumented Spasticity Assessment (ISA) with the aim of optimizing treatment algorithms and long-term response in this population.

Treatment groups

12 Participants
are divided into 1 treatment group
Group A: stroke patients treated with Botulinum toxine injections for spastic equinovarusOther 1 intervention

Trial outcomes

Primary outcomes

1

sample size calculation

To estimate the number of subjects to calculate an appropriate sample size for assessing changes in muscle, tendon and neural properties after BoNT treatment of spastic equinovarus in first-ever stroke patients by using 3DfUS and ISA in a future observational study. To calculate standard deviation and effect sizes of outcome measures obtained with 3DfUS and ISA in these patients.

Time frame
2 years

Secondary outcomes

1

muscle changes

Secondary outcome parameters measured by 3DfUS include muscle belly length for medial gastrocnemius muscle

Time frame
2 years
2

neural changes

Secondary outcome parameters measured by ISA for slow stretch measured by ISA : maximal velocity of performance (Vmax \[deg/s\])

Time frame
2 years
3

functional changes

Medical baseline data including age, gender, body mass index, time since stroke, stroke etiology, National Institute Health Stroke Scale \[15\], affected side, oral medication and adverse events will be collected at each visit from the patients medical file as they are part of standard of care:

Time frame
2 years
4

muscle changes

Secondary outcome parameters measured by 3DfUS include tendon length for medial gastrocnemius muscle

Time frame
2 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.